Drug intelligence / Profile preview

NST0037

Development stage: Preclinical
Lead developer: Neuron Biopharma
Modality: Small Molecules

Overview

NST0037 is a small molecule statin derivative being developed by Neuron Bio (a Spanish biotechnology company based in Granada) for the treatment of central nervous system disorders, specifically epilepsy and mild cognitive impairment (MCI). It belongs to a class of neuroprotective molecules derived from statins, designed to address neurodegenerative processes. The compound is currently in the preclinical stage of development, with research focused on its efficacy in screening models for cognitive and seizure-related pathologies.

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on NST0037.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NST0037.

Explore the full profile